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Summary 
Background: The antioxidant activity of estrogen has a be ne -
ficial impact in Alzheimer’s disease. A variety of clinical stu -
dies have demonstrated that estrogen replacement therapy
in postmenopausal women results in a lower frequency of
AD, delaying the onset of the neurodegenerative cascade.
On the other hand, it has been demonstrated that estrogens
may exhibit genotoxic effects, especially at elevated tissue
concentrations. Therefore, the aim of this study was to deter-
mine whether b-estradiol induces DNA damage in the
peripheral blood lymphocytes of healthy young females and
males, healthy elderly females and males and females and
males with Alzheimer’s disease. 
Methods: All experiments were performed using the alkaline
version of the Comet assay (single cell gel electrophoresis),
on six donors per each experimental group and controls. 
Results: In the Comet assay, a significant increase of DNA
migration was observed in the lymphocytes of all treated
groups (young and elderly females, young and elderly males,
AD females and AD males) at all b-estradiol concentrations
(50 mmol/L, 100 mmol/L and 250 mmol/L) used in this
investigation. In all the experiments cell viability was over
80%. 
Kratak sadr`aj
Uvod: Antioksidativna svojstva estrogena imaju povoljan
uticaj na Alchajmerovu bolest (AB). Brojne klini~ke studije
su pokazale da primena hormonske supstitucione terapije
estrogenom kod `ena u postmenopauzi smanjuje u~esta -
lost pojave AB, odla`u}i po~etak neurodegenerativnih
procesa. S druge strane, pokazano je da estrogeni mogu
ispoljiti genotoksi~an efekat, naro~ito pri povi{enim kon -
cen tracijama u tkivu. Shodno tome, cilj ove studije bio je
ispitivanje sposobnosti b-estradiola da izazove o{te}enja u
limfocitima periferne krvi zdravih mladih `ena i mu{karaca,
zdravih starih `ena i mu{karaca, kao i `ena i mu{karaca koji
boluju od Alchajmerove bolesti. 
Metode: Svi eksperimenti su izvedeni primenom alkalne
verzije komet testa (gel-elektroforeza DNK pojedina~nih
}elija), na po {est subjekata u svakoj ispitivanoj grupi. 
Rezultati: Upotrebom komet testa, zabele`eno je zna~ajno
pove}anje migracije DNK u limfocitima ispitanika iz svih
tretiranih grupa (mladih i starih `ena, mladih i starih mu -
{ka raca kao i kod `ena i mu{karaca sa AB), pri svim kon-
centracijama b-estradiola (50 mmol/L, 100 mmol/L i 250
mmol/L) koje su kori{}ene u ovoj studiji. U svim eksperi-
mentima vijabilnost }elija je bila iznad 80%. 
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Introduction
Alzheimer’s disease (AD) is the most common
form of dementia associated with ageing, manifested
as a progressive loss of memory and other cognitive
functions. It is a slow progressing disease, starting
with mild memory changes and ending in severe
brain damage (1). Genetic and environmental factors
play an important role in the AD etiology (2). Some
evidence suggests that oxidative stress is increasingly
implicated in the pathogenesis of AD as a common
feature (with abnormalities) in neurons, the glia cells,
fibroblasts as well as vascular cells from sporadic AD
patients but also from familial cases (3, 4). The etio-
logical changes such as neuronal loss and selective
neuronal degeneration affecting the hippocampus
and other cortical regions reflect gender-based pre-
dispositions of female patients with AD, which is not
the case in other neurological diseases such as
Parkinson’s disease and Huntington’s chorea (5). The
fact that the sporadic form of AD affects twice as
many women as men, and that women develop AD
mainly after the menopause, indicates that it is possi-
ble that hormonal factors may play an important role
in the loss of the differentiated phenotypes in neurons
(6, 7). These findings support the role of hormones,
especially estrogen in AD pathophysiology (8).
Estrogen has very complex effects on the CNS. A vari-
ety of clinical studies have demonstrated that estro-
gen replacement therapy in postmenopausal women
results in a lower frequency of AD, delaying the onset
of the neurodegenerative cascade (9, 10). However,
other studies show that clinical trials of estrogen in
females with mild cognitive impairment (MCI), the
phase between normal ageing and early dementia, do
not lead to cognitive improvement (11). Much evi-
dence suggests that oxidative stress is related to age-
ing and a variety of neurodegenerative disorders
including AD. Oxidative stress implies the develop-
ment of reactive oxygen species (ROS), which lead to
excessive oxidation of cellular proteins, lipids and
DNA resulting in oxidative changes and dysfunction,
leading to neuronal cell death (3). It is proposed that
estrogen might act as a neuroprotective and antioxi-
dant molecule in a lower micromolecular concentra-
tion in ageing disorders such as Alzheimer’s disease
(12). On the other hand, the role of estrogens in the
generation of ROS in cellular systems, leading to
oxidative stress (13) and DNA damage, has received
little attention.
Therefore, we have investigated the effects of
various doses of b-estradiol on peripheral blood lym-
phocytes DNA stability in elderly and young donors of
both sexes with Alzheimer’s disease. For that purpose,
the DNA Comet assay (single cell gel electrophore-
sis), a simple and sensitive technique, was used.
Materials and Methods
Participants
Blood samples were collected by venipuncture
from sporadic Alzheimer’s disease (SAD) patients,
age-matched and young adult control participants.
The Medical School Ethics Committee at the
University of Belgrade approved the study and written
informed consent was obtained from all participants
or from their families (2492/1). Diagnosis was based
on the National Institute of Neurology criteria. The
following 6 groups (n=6 subjects/group) were
included in the study: AD male, AD female, elderly
control male, elderly control female and young adult
male and young adult female. The participants’ age
Zaklju~ak: Limfociti peri ferne krvi osetljivi su na testirane
koncentracije b-estradiola, bez obzira na pol, godi{te i
zdravstveno stanje ispitanika. U skladu s navedenim nala -
zima, potvr|ena je uloga b-estradiola u izazivanju o{te}enja
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Conclusions: Lymphocytes are sensitive to the test concentra-
tions of b-estradiol in the Comet assay regardless of gender,
age and health condition of the examined subjects. There -
fore, the role of b-estradiol in cellular DNA damage has been
confirmed.
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Men Women Men Women Men Women
Average age (yr) 22.5±0.7 21.8±0.5 74.5±1.4 73.2±2.5 74.3±2.3 72.3±2.7
Age range (yr) 20–24 20–24 70–80 66–81 67–83 65–81
Average duration 
of dementia (yr) / / / / 2.8±0.8 2.8±0.7
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range, mean age and duration of dementia (for AD
groups) are summarized in Table I. Elderly controls
without a history of neurological disorders were
selected. The donors in the control groups were also
non-smokers and did not use antioxidant supple-
ments or medications known to influence the level of
oxidative stress and DNA damage. This was a double-
blind, randomized study.
Comet assay and analyses
Preparation of slides for the Comet assay was
carried out as previously described, using a modifica-
tion of the methods of Singh et al. (14). Before each
experiment, microscope slides were precoated with
1% normal agarose (Sigma, St Louis, MO) and
allowed to air dry at room temperature for at least
48h. Heparinised blood samples (4 mL) were
obtained by venipuncture from each donor. Lympho -
cytes were isolated from whole blood with Ficoll-
Paque medium and centrifuged at 1900 g for 15 min.
The lymphocytes forming a layer were directly above
Ficoll-Paque. The isolated lymphocytes were washed
twice in RPMI 1640 medium, and each wash was fol-
lowed by centrifugation for 10 min at 1800 g. Finally,
the supernatant was removed as carefully as possible
without disturbing the pellet. An aliquot of 1 mL of
RPMI 1640 was added and the pellet was resuspend-
ed. Then, 50 mL of isolated lymphocytes was mount-
ed in 50 mL of 1% low melting point agarose (LMPA)
and rapidly placed on precoated microscopic slides
covered with a coverslip, and allowed to solidify for 5
min at 4 °C. The coverslip was removed and the cells
were treated for 30 min at 37 °C to obtain the final
expe rimental concentration of b-estradiol (Sigma
Che m ical Co., St Louis, MO, CAS No. 50-28-2), 50,
100 or 250 mmol/L. Negative control was dimethyl-
sulfoxide (DMSO), a solvent of b-estradiol. Hydrogen
peroxide (H2O2) was used as the positive control at a
final concentration of 25 mmol/L. The cells were
checked for their viability before and after exposure to
b-estradiol using trypan blue dye. For each experi-
ment, untreated control samples were made. After
incubation, 90 mL of 0.5% LMPA was added as the
third layer, spread using a coverslip and allowed to
solidify at 4 °C for 5 min and the slides were placed
overnight in lysing solution (2.5 mol/L NaCl, 100
mmol/L EDTA, 10 mmol/L Tris, 1% Triton X100 and
10% DMSO, pH 10 adjusted with NaOH). After the
lysis, the slides were placed in electrophoresis buffer
(10 mol/L NaOH, 200 mmol/L EDTA, pH 13) for 30
min at 4 °C in the dark to allow DNA unwinding.
Electrophoresis was carried out for 30 min at 25 V
and 300 mA. Finally, the slides were gently rinsed
with neutralizing solution (0.4 mol/L Tris base, pH
7.5) three times, 5 min each time. Slides were stained
with 50 mL of ethidium bromide (20 mg/mL) per each
slide. The comets were observed and analyzed on an
Olympus BX 50 microscope (Olympus Optical Co.,
GmbH, Hamburg, Germany), equipped with a mer-
cury lamp HBO (50 W, 516–560 nm, Zeiss) at 100×
magnification. For each sample, 100 cells (50 for
each replicate slide) were analysed.
Evaluation of DNA damage was performed as
described by Anderson et al. (15). Namely, cells were
graded by eye into five categories corresponding to
the following amounts of DNA in the tail: (A) no dam-
age, <5%; (B) low level damage, 5–20%; (C) medi-
um level damage, 20–40%; (D) high level damage,
40–95%; (E) total damage, >95%.
DNA damage is considered as DNA migration
over 5% (B+C+D+E classes). DNA damage can be
scored by using parameter total comet score (TCS)
which is calculated from DNA damage classification
and mesured in arbitrary units. The total score was
calculated by the following equation: (percentage of
cells in class A×0)+(percentage of cells in class
B×1)+(percentage of cells in class C×2)+(percent-
age of cells in class D×3)+(percentage of cells in
class E×4) (16). Consequently, the total score was in
the range from 0 to 400. Two comet slides were used
for each donor, which makes a total of 100 comets. 
Statistical analysis
c2-test was used to assess the differences in the
total level of DNA damage in peripheral blood lym-
phocytes between young, elderly subjects and AD
patients. Wilcoxon non-parametric test was used to
compare the effect of different concentrations of b-
estradiol related to the level of DNA damage (TCS) in
peripheral blood lymphocytes. A p<0.05 was con -
sidered as significant. Statistical software GraphPad
Prism (Version 5.0) was used.
Results
This study was conducted on human peripheral
lymphocytes of three groups of individuals: AD
patients, age-matched healthy controls (elderly con-
trol) and young adult controls (young control). In
each group, subjects were subdivided according to
gender. The AD patients were affected by the spo-
radic form of the disease. We evaluated the b-estradi-
ol induced DNA damage in vitro. In each examined
group, 600 cells were scored (100 cells per person).
In all experiments the cell viability was over 80%.
There was no difference between the DNA damage
of the cells treated with the solvent (DMSO) and the
untreated cells. The mean DNA damage of positive
control in six experiments (533.16±7.19) was statis-
tically different from negative control (90.0±29.62)
(p<0.001). The b-estradiol induced DNA damage in
the examined group treated with different concentra-
tions of b-estradiol is shown in Table II.
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Evidently, analysis of the Comet assay revealed
significant differences (p<0.01) in DNA damage
after treatment with b-estradiol concentrations of 50
mmol/L, 100 mmol/L and 250 mmol/L compared to
negative control in all the test groups (AD, old and
young controls) (Table II). Also, there is a significant
difference in DNA damage between concentrations
of 250 mmol/L and 50 mmol/L (p<0.05) in all the
examined groups. It should be mentioned that a con-
centration of 250 mmol/L significantly incerased DNA
damage compared to a concentration of 100 mmol/L
in young and old controls, but this increase was not
present in AD males and females.
The TCS in peripheral blood lymphocytes is pre-
sented in Table III. In all the examined groups we
found a statistically significant difference between the
total Comet score of cells treated with DMSO (nega-
tive control) and the cells treated with b-estradiol con-
centrations of 50, 100 and 250 mmol/L. A significant
difference was detected in all the groups between the
total Comet score of cells treated with b-estradiol con-
centrations of 50 mmol/L and 100 mmol/L. The DNA
damage was statistically higher at a dose of 100
mmol/L compared with a dose of 50 mmol/L in all the
studied groups. Also, a dose of 250 mmol/L induced
statistically greater DNA damage in comparison to 50
mmol/L and 100 mmol/L in all the examined groups.
Negative control, N Estradiol, 50 mmol/L Estradiol, 100 mmol/L Estradiol, 250 mmol/L  
DNA damage in young females 62 103 a** 110 a** 141 a**;b*;c*
DNA damage in old females 93 125 a* 141 a** 174 a**; b**; c*
DNA damage in AD females 127 162 a* 181 a** 210 a**; b*
DNA damage in young males 53 94 a** 102 a** 133 a**; b*;c*
DNA damage in old males 86 116 a* 128 a** 162 a**; b*;c*
DNA damage in AD males 119 156 a* 174 a** 201 a**; b*
*, p<0.05; **, p<0.01; a vs. negative control; b vs. 50 mmol/L; c vs. 100 mmol/L
Variables are compared using c2-test.
N – the number of cells
Negative control 50 mmol/L 100 mmol/L 250 mmol/L  
Young females 26.83±10.62 48.00±12.65 a* 57.00±7.24 a*;b* 78.50±14.35 a*;b*;c*
Old females 41.17±15.19 58.17±16.91 a* 72.50±22.62 a*;b* 87.83±8.19 a*;b*;c*
AD females 57.17±10.92 77.67±13.22 a* 92.83±12.32 a*;b* 109.33±15.31a*;b*;c*
Young males 23.50±16.57 45.00±15.51 a* 53.00±15.07 a*;b* 74.17±11.77 a*;b*;c*
Old males 42.33±10.35 57.00±16.36 a* 66.83±11.89 a*;b* 93.00±20.51 a*;b*;c*
AD males 54.83±20.67 71.33±18.65 a* 88.50±21.95 a*;b* 106.67±20.43a*;b*;c*
Table III Total Comet Score of lymphocytes of the examined group treated with different concentrations of b-estradiol.
*, p<0.05; a vs. negative control; b vs. 50 mmol/L; c vs. 100 mmol/L
Variables are compared using Wilcoxon non-parametric test.
Table II DNA damage in the examined group, induced by different concentrations of b-estradiol. The Comet assay was performed
30 min after the treatment (100 comets counted per experiment).
There were no significant sex-dependent differ-
ences in untreated DNA damage in AD patients and
control groups. Regarding b-estradiol induced gender
dependent DNA damage, there were no significant
differences in DNA damage between males and
females after b-estradiol treatment in all the exam -
 ined groups. Therefore, the applied concentration of
b-estra diol caused a statistically significant positive
response in the Comet assay in all the groups, regard-
less of gender.
On the other hand, Figure 1 shows a statistical-
ly significant difference in the frequency of DNA dam-
age was observed between the AD group and elderly
controls. The frequencies of DNA damage were sig-
nificantly increased in male patients with AD
(p<0.05) when compared to those of the correspon-
ding controls. Likewise, females diagnosed with AD
also displayed a significant and marked increase in
the frequency of DNA damage (p<0.05) in compari-
son to control group values. Comparisons between
young individuals and the elderly group showed sig -
 nificant differences (p=0.51) among the two groups,
displaying higher percentages of DNA damage
(p<0.01) in the elderly males and females.
Discussion
Lymphocytes are among the most frequently
chosen biological material to study harmful effects
resulting from metabolic changes, induced by tested
compounds in different concentrations (17). Using
the alkaline version of the Comet assay, we have
assessed DNA damage by using various therapeutic
concentrations of b-estradiol in the peripheral blood
lymphocytes of Alzheimer’s disease, elderly and
young donors.
The results of these investigations demonstrate
that there is a clear enhancement in the level of DNA
damage in the peripheral blood lymphocytes of both
genders in all the abovementioned treatment groups,
treated with different concentrations of b-estradiol. In
this study, it was confirmed that cells were sensitive to
30 min treatment with b-estradiol at tested concen-
trations (50, 100 and 250 mmol/L). It was also
noticed, from the number of comet-like nuclei, that
there is a clear dose-dependent increase in DNA
damage in all the groups.
Though Alzheimer’s disease is considered a
neurodegenerative disorder, investigation in non-
neuro nal cells is equally important, not only for shed-
ding light on the etiology of the disease, but also for
possible diagnostic purposes and monitoring the
progress of the disease. For the evaluation of frequen-
cy and the level of DNA damage among the three
treatment groups used in this study, the Comet assay
was used as an invaluable method for exploring fun-
damental aspects of DNA damage and how the cell
consequently responds to stress (18). The results of
this work demonstrate the presence of genomic insta-
bility in peripheral blood lymphocytes, both in AD
patients and healthy subjects of the same age catego-
ry in relation to the young. Based on the number of
cells with DNA damage, the expression of genetic
instability is more prominent in AD subjects compa -
red to age-matched controls (19–21). It is accepted
that oxidative stress plays a major role in the patholo-
gy of Alzheimer’s disease (22–24). Oxidative stress
represents the loss of balance between the processes
of the creation of free radicals and those that are
responsible for the removal of oxidized macromole-
cules (antioxidative cascade) which again leads to cel-
lular dysfunction (changes in cellular homeostasis)
and results in increased genomic instability and even-
tually in cell death (25). Most likely, the oxidative
stress is the essence of a greater DNA damage com-
pared to adequate control (18, 26, 27) as one of the
initial factors that lead to further genomic instability
(28–30). There is substantial evidence supporting the
fact that genetic instability is increased in AD lympho-
cytes compared to corresponding controls. An impor-
tant aspect of genetic research related to AD is the
analysis of lymphocytes chromosome instability which
in cludes: aneuploidies of different chromosomes, te -
lo mere shortening and the phenomenon of prema-
ture centomere division (31–33). Also, an im paired
DNA repair mechanism, particularly the base excision
re pair pathway, might play an essential role in Alzhei -
mer’s disease (34).
Because of their lipofilic nature, steroid hormo nes
can freely and quickly cross the cell membranes (35).
Since lymphocytes express receptors for estrogens as
well, the steroid hormone has the ability to cross cel-
lular membranes and allows binding to nuclear recep-
tors exibiting genomic action by altering gene expres-
sion and changing DNA (36).


























Figure 1 DNA damage of three groups of individuals: AD
patients, elderly controls and young controls. 
*, p<0.05; **, p<0.01; a vs. young; b vs. old
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Recent research has shown that estrogens can
be involved in redox cycling because of the presence
of a phenolic group in the molecule which can be
converted to catechol estrogens (37). Free radical
generation by redox cycling of catechol estrogens and
catechol estrogens-derived quinones are known to
produce DNA adducts (38) such as 8-hydroxy-
deoxyguanosine (39). Chemically modified bases can
be further turned into DNA breakage due to the
incomplete repair of damaged bases. The deleterious
prooxidant effects of catechol estrogens are displayed
by the presence of redox-active metal ions in high tis-
sue concentrations. The effects of oxygen free radi-
cal-mediated toxicity become evident throught forma-
tion of single-strand DNA brakes (40). In agreement
with the previous findings, this work confirms that
high experimental concentrations of b-estradiol create
oxidative stress and oxidative radical DNA damage.
Experimental findings support this assumption, show-
ing that the antioxidant enzyme catalase succesfully
attenuates DNA damaging effects induced by estradi-
ol in the Comet assay, both in human lymphocytes
(41, 42) and sperm (13). Thus, if tested concentra-
tions of b-estradiol influence the extent of endoge-
nous oxidative DNA damage in lymphocytes, similar
differences should be visible in the level of DNA dam-
age in the examined cells from tested groups.
Our study demonstrates that b-estradiol within
the range of investigated concentrations does not ex -
hibit protective and antioxidant effects on lym phocy -
tes in AD patients. In elderly and Alzheimer’s disease
subjects b-estradiol causes an additional in cre ase of
basal DNA damage. Investigated con cen trations of b-
estradiol enhance oxidative processes during ageing
and neurodegenerative processes characteristic for
AD. Our results favor the group of re sear chers who
be lieve that estrogen therapy does not lead to cogni-
tive improvement. It would be useful to exa mine the
in fluences of such estrogen concentrations in vivo,
that is, in patients on adequate estrogen the rapy.
Therefore, it can be concluded that lymphocytes
are sensitive to test concentrations of b-estradiol in
the Comet assay regardless to gender, age and the
health condition of examined subjects. The role of
b-es tradiol in cellular DNA damage has been con-
firmed.
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